Emerging Drugs and Indications for Cardio-Metabolic Disorders in People with Severe Mental Illness

Author(s): Youssef Kouidrat, Ali Amad, Marc De Hert

Journal Name: Current Pharmaceutical Design

Volume 21 , Issue 23 , 2015

Become EABM
Become Reviewer


Patients with severe mental illnesses, such as schizophrenia and bipolar disorder, are at increased risk of developing metabolic disorders including obesity, diabetes, and dyslipidemia. All of these comorbidities increase the risk of cardiovascular disease and mortality. Different approaches, including diet and lifestyle modifications, behavioral therapy and switching antipsychotic agents, have been proposed to manage these metabolic abnormalities. However, these interventions may be insufficient, impractical or fail to counteract the metabolic dysregulation. Consequently, a variety of pharmacological agents such as antidiabetic drugs, have been studied in an attempt to reverse the weight gain and metabolic abnormalities evident in these patients. Despite a significant effect, many of these treatments are used off-label. This qualitative review focuses on pharmacological agents that could offer significant benefits in the management of cardio-metabolic disorders associated with serious mental illness.

Keywords: Antipsychotic-induced weight gain, bipolar disorder, cardiovascular risk, metformin, metabolic syndrome, off-label use, schizophrenia, severe mental illness.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [3317 - 3324]
Pages: 8
DOI: 10.2174/1381612821666150619093128
Price: $65

Article Metrics

PDF: 40